The partnership is likely to be viewed positively by investors and the market, as it leverages SOPHiA GENETICS's strengths in genomics and bioinformatics, potentially leading to new product developments and market expansion. This strategic move could enhance SOPH's competitive edge in the precision medicine industry, likely resulting in a positive short-term impact on its stock price.